What's Next For NAMs? Moving From Barriers To Breakthroughs

New Approach Methodologies (NAMs) are gaining momentum as viable alternatives to traditional preclinical testing approaches, supported by advances in organoids, organ-on-a-chip systems, and computational modeling. Yet scientific innovation alone is not enough to drive widespread adoption. The future of NAMs depends on strengthening the biological systems that power these models, establishing standards that enable meaningful comparison across studies, and generating the robust evidence regulators need to evaluate new approaches with confidence.

As regulatory agencies increasingly embrace non-animal methods, organizations face a critical opportunity to prepare for a rapidly evolving development landscape. Success will require well-characterized cell sources, reproducible study designs, collaborative data sharing, and submission-ready research practices that prioritize data integrity and traceability. Equally important is benchmarking NAMs against human outcomes rather than relying solely on comparisons to traditional animal models. By addressing these challenges, the industry can accelerate regulatory confidence, improve human relevance in preclinical research, and move NAMs from promising innovation to routine practice.

Explore the full article for insights into the scientific, operational, and regulatory developments shaping the next phase of NAMs adoption.